Monkasta (Montelukast)

Montelukast, the active ingredient in Monkasta, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used for maintenance therapy of asthma, allergic rhinitis, and exercise‑induced bronchoconstriction. GNH USA supplies Monkasta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is a leukotriene receptor antagonist that manages conditions driven by cysteinyl leukotrienes.

- Asthma: improves long‑term control and reduces the frequency of symptoms. - Allergic rhinitis: relieves nasal congestion, sneezing and itching. - Exercise‑induced bronchoconstriction: prevents bronchospasm triggered by physical activity.

Common Side Effects: - Headache: mild to moderate pain often transient. - Abdominal pain: discomfort or cramping in the stomach area. - Cough: occasional dry cough. - Nausea: feeling of unease or urge to vomit.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips or throat that may impair breathing. - Stevens‑Johnson syndrome: severe skin reaction with blistering and detachment. - Mood changes: depression, anxiety, or suicidal thoughts requiring immediate medical attention.

Before prescribing Monkasta, consider the following precautions: - Assess liver function: monitor patients with existing hepatic disease. - Review psychiatric history: observe for mood alterations or depressive symptoms. - Avoid use in patients with known hypersensitivity to montelukast or any component of the formulation. - Use caution in severe renal impairment: dose adjustment may be required. - Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Montelukast may interact with other medicines as follows.

Major Interactions (Avoid): - Rifampin: enzyme induction reduces montelukast plasma levels. - Phenobarbital: increases metabolism, potentially lowering efficacy. - Ketoconazole: CYP3A4 inhibition may raise montelukast concentrations.

Moderate Interactions (Monitor Closely): - Beta‑agonists: additive bronchodilator effect may require monitoring. - NSAIDs: may increase risk of hepatic enzyme elevation. - Oral contraceptives: possible reduction in contraceptive effectiveness.